MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

TG Therapeutics Inc

Closed

SectorHealthcare

37.9 -3.29

Overview

Share price change

24h

Current

Min

37.61

Max

39.12

Key metrics

By Trading Economics

Income

-18M

5.1M

Sales

13M

121M

P/E

Sector Avg

155.68

39.857

Profit margin

4.187

Employees

352

EBITDA

-20M

12M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-3.04% downside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

1.4B

6.2B

Previous open

41.19

Previous close

37.9

News Sentiment

By Acuity

50%

50%

154 / 376 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

TG Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

19 Aug 2024, 20:01 UTC

Earnings

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter -- IBD

Peer Comparison

Price change

TG Therapeutics Inc Forecast

Price Target

By TipRanks

-3.04% downside

12 Months Forecast

Average 38 USD  -3.04%

High 50 USD

Low 11 USD

Based on 5 Wall Street analysts offering 12 month price targets forTG Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

3

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

N/A / 34.86Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

154 / 376 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.